Skip to main content

Table 1 Patient characteristics and disease parameters

From: Evaluation of treatments for sacroiliitis in spondyloarthropathy using the Spondyloarthritis Research Consortium Canada scoring system

 

All

Anti-TNF alone

Anti-TNF + DMARDs

DMARDs alone

Age (years)

21 (15–36)

23 (15–29)

27 (18–32)

28 (22–36)

Gender (male/female)

12/44

3/15

6/15

3/14

Disease duration

2 (0.17–10)

0.67 (0.17–3)

2 (0.75–6)

7.5 (3.5–10)

HLA-B27-positive

91.1 % (51/56)

88.9 % (16/18)

90.5 % (19/21)

94.1 % (16/17)

Baseline

 SPARCC

32.45 ± 18.71

27.76 ± 18.38

39.53 ± 19.21

28.67 ± 15.51

 ASDAS

2.84 ± 1.26

2.56 ± 1.24

3.58 ± 1.05

2.21 ± 1.03

 ESRa

27.10 ± 32.39

27.94 ± 33.24

38.49 ± 38.50

12.14 ± 8.43

 CRPa

17.50 ± 23.07

16.29 ± 23.05

26.29 ± 28.02

7.919 ± 5.60

  1. aNot normally distributed, compared by paired rank test
  2. ASDAS Ankylosing Spondylitis Disease Activity Indices, CRP C-reactive protein, DMARD disease-modifying anti-rheumatic drug, ESR erythrocyte sedimentation rate, SPARCC Spondyloarthritis Research Consortium Canada, TNF tumor necrosis factor